Trial Profile
A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Apr 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Glioma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 14 Apr 2021 A population pharmacokinetic model was developed for sunitinib and SU012662 in pediatric patients with GIST or other solid tumors, results published in the European Journal of Drug Metabolism and Pharmacokinetics
- 20 Jul 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 14 Dec 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.